These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Phosphate binders in moderate chronic kidney disease: where do we stand? Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481 [TBL] [Abstract][Full Text] [Related]
7. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389 [TBL] [Abstract][Full Text] [Related]
8. Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT). Adema AY; de Jong MA; de Borst MH; Ter Wee PM; Vervloet MG; Nephron; 2016; 134(4):215-220. PubMed ID: 27442253 [TBL] [Abstract][Full Text] [Related]
9. The role of calcium and non calcium-based phosphate binders in chronic kidney disease. Elder GJ; Center J Nephrology (Carlton); 2017 Mar; 22 Suppl 2():42-46. PubMed ID: 28429551 [TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467 [TBL] [Abstract][Full Text] [Related]
11. [Strategies aiming to control hyperphosphatemia in chronic kidney disease]. Ureña Torres PA Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750 [TBL] [Abstract][Full Text] [Related]
12. Oral phosphate binders in CKD - is calcium the (only) answer? Goldsmith D; Covic A Clin Nephrol; 2014 Jun; 81(6):389-95. PubMed ID: 25017668 [TBL] [Abstract][Full Text] [Related]
13. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Patel L; Bernard LM; Elder GJ Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024 [TBL] [Abstract][Full Text] [Related]
14. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders. Noto L J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905 [TBL] [Abstract][Full Text] [Related]
16. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Zhao SJ; Wang ZX; Chen L; Wang FX; Kong LD Ann Palliat Med; 2022 Apr; 11(4):1264-1277. PubMed ID: 34775773 [TBL] [Abstract][Full Text] [Related]
17. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Soriano S; Ojeda R; Rodríguez M; Almadén Y; Rodríguez M; Martín-Malo A; Aljama P Clin Nephrol; 2013 Jul; 80(1):17-22. PubMed ID: 23391319 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease. Habbous S; Przech S; Martin J; Garg AX; Sarma S Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost-efficacy of phosphate binders in hemodialysis. Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491 [TBL] [Abstract][Full Text] [Related]
20. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Di Iorio B; Bellasi A; Russo D; Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]